2. Signaling Pathways
  3. Immunology/Inflammation
  4. PD-1/PD-L1
  5. PD-1/PD-L1 Antagonist

PD-1/PD-L1 Antagonist

PD-1/PD-L1 Antagonists (5):

Cat. No. Product Name Effect Purity
  • HY-P1812
    AUNP-12
    		Antagonist 99.31%
    AUNP-12 (NP-12) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. AUNP-12 exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs).
  • HY-P1812A
    AUNP-12 TFA
    		Antagonist
    AUNP-12 TFA (NP-12 TFA) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. AUNP-12 TFA exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs).
  • HY-161748
    PD-1/PD-L1-IN-46
    		Antagonist
    PD-1/PD-L1-IN-46 (compound (R)-C27 ) is an PD-1/PD-L1 antagonist with IC50 value of 18.66 nM.
  • HY-P10439
    CVRARTR
    		Antagonist
    CVRARTR is an antagonist for programmed cell death ligand-1 (PD-L1) with KD of 281 nM. CVRARTR induces the internalization of PD-L1 and downregulates PD-L1 on the cell surface. CVRARTR restores cytokine secretion and T cell proliferation in cell CT26. CVRARTR exhibits antitumor efficacy against in CT26 homograft mouse model.
  • HY-158052
    PD-1/PD-L1 antagonist 1
    		Antagonist
    PD-1/PD-L1 antagonist 1 (Compound A5) is an antagonist for programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) interaction, with an IC50 of 23.78 nM.